Washington, D.C. 20549 __________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q _________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-39156 Delaware 27-2404165 (I.R.S. Employer Identification No.) ...

Exhibit 99.1 PRESS RELEASE Curis Provides Third Quarter 2025 Business Update Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., November 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its financial and operating results for the third quarter ended September 30, 2025. "We made good progress advancing our clinical stu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38609 KLX Energy Services Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 36-4904146 (State of Inco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 32-0125724 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39471 HERITAGE GLOBAL INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Org ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of principal executive offices including zip code) (State or other jurisdiction of incorporation or organization) Delaware 45-3757789 (I.R.S. Employer Identification No.) P.O. Box 125 Stewartsville, New Jersey 08886 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SEC ...

Washington, D. C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2025 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission file number: 01-07698 ACME UNITED CORPORATION (Exact Name of Registrant as Specified in Its Charter) Connecticut 06-0236700 Address of Principal Executive Offices Zip Code Registrant's telephone number, including area code: (203) 254-6060 ☐ TRANSITION REPORT PURSUANT TO SE ...

Exhibit 99.1 o DS . . · : i . . III 00000 Q3 2025 | Key Financial | Revenue | | | --- | --- | --- | | Measures | | 10% Y/Y | | | | 10% Y/Y (ex-FX) | | | Net Income | $1.4B | | | | 34% Net income margin | | | Adjusted EBITDA* | $2.1B | | | | 50% Adjusted EBITDA Margin | | | Free Cash Flow ("FCF")* | $1.3B | | | | 33% FCF Margin | | | Trailing Twelve Month ("TTM") FCF* | 4.5B | | | | 38% TTM FCF Margin | | Key Business | Gross Booking | $22.9B | | Metrics | Value ("GBV") | | | | | 14% Y/Y 12% Y/Y (ex-FX) | | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF ONCOLOGY, INC. (Registrant's telephone number, including area code) | Title of each class: | Trading Symbol ...